Therapy Detail

Therapy Name Paclitaxel + Carboplatin
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Carboplatin Paraplatin CBDCA Chemotherapy - Platinum 6 Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).
Paclitaxel Taxol 7-Epipaclitaxel Antimicrotubule Agent 11 BCL2 Family Inhibitor 6 Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02163694 Phase III Veliparib Paclitaxel + Carboplatin A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer Active, not recruiting
NCT03745222 Phase III BGB-A317 BGB-A317 + Cisplatin + Etoposide BGB-A317 + Carboplatin + Paclitaxel Cisplatin + Etoposide Paclitaxel + Carboplatin A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001) Recruiting
NCT02412371 Phase II Veliparib Paclitaxel + Carboplatin A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer Active, not recruiting
NCT03800134 Phase III Cisplatin + Durvalumab + Gemcitabine Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Carboplatin + Durvalumab + Pemetrexed Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Pemetrexed Gemcitabine + Cisplatin A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer Recruiting
NCT02876107 Phase II Doxorubicin + Cyclophosphamide Carboplatin + Paclitaxel + Panitumumab Paclitaxel + Carboplatin A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC) Recruiting
NCT01711541 Phase Ib/II Carboplatin + Etoposide + Veliparib Cisplatin + Fluorouracil + Hydroxyurea Paclitaxel + Carboplatin Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer Active, not recruiting
NCT02358200 Phase I Paclitaxel + Carboplatin Talazoparib Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer Active, not recruiting
NCT01367002 Phase II Trastuzumab Paclitaxel + Carboplatin Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Active, not recruiting
NCT01966003 Phase III Bevacizumab Bevacizumab-awwb Paclitaxel + Carboplatin Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer Completed
NCT01616303 Phase II Oregovomab + Carboplatin + Paclitaxel Paclitaxel + Carboplatin A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer Completed
NCT02998268 Phase II Pembrolizumab Paclitaxel + Carboplatin Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Recruiting
NCT02476955 Phase I ARQ092 Paclitaxel + Carboplatin Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel Recruiting
NCT01769391 Phase II Necitumumab Paclitaxel + Carboplatin A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer Completed
NCT02220894 Phase III Pemetrexed Paclitaxel + Carboplatin Pembrolizumab Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Active, not recruiting
NCT01868022 Phase I Docetaxel Cisplatin + Pemetrexed GSK3052230 Paclitaxel + Carboplatin Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Completed
NCT02542293 Phase III Gemcitabine + Cisplatin Carboplatin + Gemcitabine Durvalumab + Tremelimumab Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). Active, not recruiting
NCT02436993 Phase II Bevacizumab Pertuzumab + Trastuzumab Paclitaxel + Carboplatin Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Recruiting
NCT00980954 Phase III Paclitaxel + Carboplatin Cisplatin Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting
NCT02186847 Phase II Metformin Paclitaxel + Carboplatin Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Active, not recruiting
NCT01196390 Phase III Paclitaxel + Carboplatin + Trastuzumab Paclitaxel + Carboplatin Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting
NCT02032277 Phase III Doxorubicin + Cyclophosphamide Veliparib Carboplatin Paclitaxel + Carboplatin A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer Active, not recruiting
NCT02124421 Phase II Paclitaxel + Carboplatin Cisplatin + Paclitaxel Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer Recruiting
NCT02730546 Phase Ib/II Paclitaxel + Carboplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery Recruiting
NCT03694002 Phase II Paclitaxel + Carboplatin Ramucirumab + Paclitaxel + Carboplatin Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Recruiting
NCT02591615 Phase II Pembrolizumab Paclitaxel + Carboplatin Carboplatin + Pemetrexed Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC Recruiting
NCT01803282 Phase I GS-5745 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed FOLFIRI Nab-paclitaxel + Gemcitabine Paclitaxel + Carboplatin Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Active, not recruiting
NCT03604991 Phase II Paclitaxel + Carboplatin Nivolumab Nivolumab + Carboplatin + Paclitaxel Nivolumab + Ipilimumab Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma Recruiting
NCT02520154 Phase II Paclitaxel + Carboplatin Pembrolizumab Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer Recruiting
NCT02775435 Phase III Carboplatin + nab-paclitaxel Pembrolizumab Paclitaxel + Carboplatin A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Active, not recruiting
NCT00954174 Phase III Paclitaxel + Carboplatin Paclitaxel + Ifosfamide Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer Active, not recruiting
NCT03635567 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Paclitaxel + Carboplatin Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Recruiting
NCT02713386 Phase Ib/II Ruxolitinib Paclitaxel + Carboplatin Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting
NCT02051868 Phase II Paclitaxel + Carboplatin Cisplatin + Fluorouracil International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT) Unknown status
NCT02429843 Phase I Paclitaxel + Carboplatin Bevacizumab Carotuximab A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer Active, not recruiting
NCT02317874 Phase I Paclitaxel + Carboplatin Talazoparib PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting
NCT02272413 Phase III Paclitaxel + Carboplatin Bevacizumab Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer Completed
NCT01506609 Phase II Veliparib + Temozolomide Carboplatin + Etoposide + Veliparib Paclitaxel + Carboplatin The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer Active, not recruiting
NCT02106546 Phase III Veliparib Paclitaxel + Carboplatin Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Active, not recruiting
NCT02658214 Phase I Carboplatin + Gemcitabine Carboplatin + nab-paclitaxel Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Durvalumab + Tremelimumab Paclitaxel + Carboplatin Carboplatin + Etoposide Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Active, not recruiting
NCT02718417 Phase III Avelumab Paclitaxel + Carboplatin Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) Active, not recruiting
NCT03036488 Phase III Epirubicin + Cyclophosphamide Doxorubicin + Cyclophosphamide Pembrolizumab Paclitaxel + Carboplatin Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Active, not recruiting
NCT02530437 Phase Ib/II Taladegib Paclitaxel + Carboplatin A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction Active, not recruiting
NCT01993810 Phase III Carboplatin + Pemetrexed Durvalumab Cisplatin + Etoposide Paclitaxel + Carboplatin Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Recruiting
NCT03322566 Phase III Epacadostat + Pembrolizumab Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Pembrolizumab Plus Epacadostat Alone or With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT02453282 Phase III Durvalumab Gemcitabine + Cisplatin Paclitaxel + Carboplatin Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). Active, not recruiting
NCT02525757 Phase II Atezolizumab Paclitaxel + Carboplatin MPDL3280A With Chemoradiation for Lung Cancer Active, not recruiting
NCT03740165 Phase III Bevacizumab + Carboplatin + Paclitaxel Paclitaxel + Carboplatin Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab + Olaparib Carboplatin + Paclitaxel + Pembrolizumab + Olaparib Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/KEYLYNK-001) Recruiting
NCT01578551 Phase II Metformin Paclitaxel + Carboplatin Bevacizumab A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. Terminated
NCT03003962 Phase III Durvalumab Gemcitabine + Cisplatin Carboplatin + Gemcitabine Carboplatin + Pemetrexed Cisplatin + Pemetrexed Paclitaxel + Carboplatin Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer Recruiting
NCT02065687 Phase III Paclitaxel + Carboplatin + Metformin Paclitaxel + Carboplatin Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting
NCT02513563 Phase II Paclitaxel + Carboplatin Adavosertib AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer Recruiting
NCT00979212 Phase II Panitumumab Paclitaxel + Carboplatin Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10) Active, not recruiting
NCT02883062 Phase II Paclitaxel + Carboplatin Atezolizumab + Carboplatin + Paclitaxel Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer Suspended
NCT01386385 Phase Ib/II Paclitaxel + Carboplatin Carboplatin + Etoposide + Veliparib Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting